Read More

Advancing a broad pipeline of differentiated product candidates for chronic inflammatory diseases.

Development Pipeline

Driving meaningful advances to address chronic inflammation.

We’re committed to evolving immunology, with a pipeline of programs specifically designed to address inflammatory diseases with clear, unmet needs. The disease pathways under investigation by Evommune exert influence on a multitude of disease areas, and the modulation of mast cell, sensory neuron and T-cell activity shows promise in multiple established patient populations.

Program
Target
Indication
  • Discovery
  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
MRGPRX2
Chronic Spontaneous Urticaria Atopic Dermatitis Migraine Other Indications
IL-18
Atopic Dermatitis Ulcerative Colitis

Program
Target
MRGPRX2
Indication
Stage
Chronic Spontaneous Urticaria
Atopic Dermatitis
Migraine
Other Indications
Phase 2
Phase 2
Phase 1
Phase 1
Program
Target
IL-18
Indication
Stage
Atopic Dermatitis
Ulcerative Colitis
Phase 2
Phase 1

Learn about our ongoing clinical trials for our investigational therapies.